Drugs / autoclaved leishmania antigen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001906 | Apr 1999 → May 2001 | cutaneous leishmaniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autoclaved leishmania antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001906 ↗ |
| Modality | Vaccine | “We have shown excellent protection using a "heat-killed" vaccine that combines autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum...” NCT00001906 ↗ |